Breast cancer could be detected up to five years before there are any clinical signs of it, using a blood test that identifies the body’s immune response to substances produced by tumour cells, according to new research presented at the 2019 NCRI Cancer Conference today (Sunday).
Cancer cells produce proteins called antigens that trigger the body to make antibodies against them – autoantibodies. Researchers at the University of Nottingham (UK) have found that these tumour-associated antigens (TAAs) are good indicators of cancer, and now they have developed panels of TAAs that are known already to be associated with breast cancer to detect whether or not there are autoantibodies against them in blood samples taken from patients.
In a pilot study the researchers, who are part of the Centre of Excellence for Autoimmunity in Cancer (CEAC) group at the School of Medicine, University of Nottingham, took blood samples from 90 breast cancer patients at the time they were diagnosed with breast cancer and matched them with samples taken from 90 patients without breast cancer (the control group).
They used screening technology (protein microarray) that allowed them to screen the blood samples rapidly for the presence of autoantibodies against 40 TAAs associated with breast cancer, and also 27 TAAs that were not known to be linked with the disease.
Presenting the research at the NCRI Conference, Ms Daniyah Alfattani, a PhD student in the group, said: “The results of our study showed that breast cancer does induce autoantibodies against panels of specific tumour-associated antigens. We were able to detect cancer with reasonable accuracy by identifying these autoantibodies in the blood.”
The researchers identified three panels of TAAs against which to test for autoantibodies. The accuracy of the test improved in the panels that contained more TAAs. The panel of five TAAs correctly detected breast cancer in 29% of the samples from the cancer patients and correctly identified 84% of the control samples as being cancer-free. The panel of seven TAAs correctly identified cancer in 35% of cancer samples and no cancer in 79% of control samples. The panel of nine antigens correctly identified cancer in 37% of cancer samples and no cancer in 79% of the controls.
“We need to develop and further validate this test,” said Ms Alfattani. “However, these results are encouraging and indicate that it’s possible to detect a signal for early breast cancer. Once we have improved the accuracy of the test, then it opens the possibility of using a simple blood test to improve early detection of the disease.”
The researchers are now testing samples from 800 patients against a panel of nine TAAs, and they expect the accuracy of the test to improve with these larger numbers.
“A blood test for early breast cancer detection would be cost effective, which would be of particular value in low and middle income countries. It would also be an easier screening method to implement compared to current methods, such as mammography,” said Ms Alfattani.
The researchers estimate that, with a fully-funded development programme, the test might become available in the clinic in about four to five years.
A similar test for lung cancer is currently being tested in a randomised controlled trial in Scotland, involving 12,000 people at high risk of developing lung cancer because they smoke. They have been randomised to have (or not) an autoantibody blood test called ELISA (Early CDT-Lung). Participants who test positive for the autoantibodies are then followed up with a CT scan every two years in order to detect lung cancer in its early stages when it is easier to treat.
The CEAC group is also working on similar tests for pancreatic, colorectal and liver cancers. Solid tumours like these, as well as lung and breast cancer, represent around 70% of all cancers.
“A blood test capable of detecting any of these cancers at an early stage is the over-riding objective of our work,” concluded Ms Alfattani.
Dr Iain Frame, CEO of NCRI said: “Early diagnosis using simple, non-invasive ways of detecting the first signs of cancer is a key strategic priority for NCRI and something we’d all like to see working in practice. The results from this pilot study for a blood test to detect early breast cancer are promising and build on this research group’s expertise in other cancers, such as lung cancer. It’s obviously early days but we look forward to seeing the results from the larger group of patients that are now being investigated.”
The Latest on: Breast cancer
via Google News
The Latest on: Breast cancer
- Trial vaccine wipes out breast cancer in Florida patient on November 18, 2019 at 10:48 am
LAKE MARY, Fla. - A Florida woman is the first patient to kill off breast cancer with the help of a promising new vaccine. Lee Mercker, from the Jacksonville area, was diagnosed with a very ...
- How to reduce the risk of breast cancer on November 18, 2019 at 10:24 am
HOUSTON — Dr. Therese Bevers with The University of Texas MD Anderson Cancer Center stopped by to share knowledge on breast cancer prevention. For more information on The University of Texas MD ...
- Expert: Herbal aids can slow wound healing in breast cancer spread to skin on November 18, 2019 at 10:20 am
Using herbal products to treat breast cancer that's spread to the skin could slow wound healing and interfere with chemotherapy or hormone treatment, an expert warns. Many patients try herbal products ...
- Facebook relents after breast cancer tattoo artist stages protest on November 18, 2019 at 10:01 am
Uncovered female nipples are included in this policy. After the Facebook reversal, Martin was quick to test her feed to see if the protest had worked. “This is post-mastectomy breast cancer, she wrote ...
- Advanced breast cancer patients denied access to life-prolonging drugs and opioids on November 18, 2019 at 5:52 am
Survival for patients with the most common forms of advanced breast cancer could be substantially improved if both younger and older patients had access to a group of anti-cancer drugs called CDK4/6 ...
- Breast cancer survivors 'in dire need' of life-saving drug on November 18, 2019 at 3:00 am
A problem that I hope to never face again." She is one of approximately 150 Islanders using Tamoxifen, according to Health PEI. It's an oral drug used to treat breast cancer and help prevent it from ...
- Breast Cancer Imaging Market May Set New Growth Story | GE Healthcare, Siemens Healthineers, Hologic on November 18, 2019 at 2:43 am
Nov 18, 2019 (HTF Market Intelligence via COMTEX) -- HTF MI recently introduced Global Breast Cancer Imaging Market study with in-depth overview, describing about the Product / Industry Scope and ...
- Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression on November 18, 2019 at 2:28 am
We sought to determine the frequency and importance of DARPP-32 expression in two large independent cohorts of early stage invasive breast cancer patients, including an additional cohort of HER2 ...
- Neutrophil-lymphocyte ratio in metastatic breast cancer is not an independent predictor of survival, but depends on other variables on November 18, 2019 at 2:13 am
The prognostic impact of neutrophil-lymphocyte ratio (NLR) in metastatic breast cancer (MBC) has been previously evaluated in early and metastatic mixed breast cancer cohorts or without considering ...
- BRIEF-Roche To Present Data For 7 Approved And Investigational Medicines Across Multiple Types Of Breast Cancer on November 17, 2019 at 10:15 pm
* FOLLOW-UP DATA FROM PIVOTAL PHASE III APHINITY STUDY EVALUATING PERJETA PLUS HERCEPTIN AND CHEMOTHERAPY IN HER2-POSITIVE EARLY BREAST CANCER * RESULTS FROM PHASE III FEDERICA STUDY CONFIRMING ...
via Bing News